Allison Mah1, Mark W Hull2, Kora DeBeck3, Michael John Milloy2, Sabina Dobrer4, Ekaterina Nosova4, Evan Wood2, Thomas Kerr2, Kanna Hayashi5. 1. Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 2. Department of Medicine, University of British Columbia, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 3. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; School of Population and Public Health, University of British Columbia, 5804 Fairview Avenue, Vancouver, BC, V6T 1Z3, Canada. 4. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada. 5. British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, 608-1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada; Faculty of Health Sciences, Simon Fraser University, Blusson Hall, 8888 University Drive, Burnaby, BC, V5A 1S6, Canada. Electronic address: uhri-kh@cfenet.ubc.ca.
Abstract
BACKGROUND: Knowledge of hepatitis C virus (HCV) is believed to be important in altering risk behaviour, improving engagement in care, and promoting willingness to initiate HCV treatment. We assessed factors associated with HCV knowledge and treatment willingness amongst people who inject drugs (PWID) in an era of direct acting antivirals. METHODS: Data were derived from three prospective cohort studies of PWID in Vancouver, Canada, between June 2014 and May 2015. HCV knowledge and treatment willingness were assessed using a Likert scale. Multivariable linear regression identified factors associated with higher HCV knowledge and treatment willingness. RESULTS: Amongst 630 participants, mean scores for HCV knowledge and treatment willingness were 25.41 (standard deviation [SD]: 2.52) out of 30, and 6.83 (SD: 1.83) out of 10, respectively. In multivariable analyses, Caucasian ancestry (adjusted linear regression model estimate [β] 0.50; 95% confidence interval [CI] 0.17, 0.82), employment (β 0.76; 95% CI: 0.38, 1.13), diagnosed mental health disorder (β 0.44; 95% CI: 0.11, 0.78) and previous HCV treatment (β 0.94; 95% CI: 0.46, 1.43) were independently associated with higher knowledge. Downtown Eastside (DTES) residence (i.e., epicenter of Vancouver's drug scene) was independently associated with lower knowledge (β -0.48; 95% CI: -0.81, -0.15). Greater HCV knowledge (β 0.12; 95% CI: 0.07, 0.17) was independently associated with higher HCV treatment willingness. DTES residence (β -0.31; 95% CI: -0.56, -0.06) and daily crack cocaine smoking (β -0.52; 95% CI: -0.92, -0.13) were independently associated with lower treatment willingness. CONCLUSION: Socioeconomic factors, such as neighborhood residence and employment, were associated with HCV knowledge. Higher HCV knowledge was associated with more HCV treatment willingness. Our findings suggest that increasing HCV knowledge amongst PWID may be an integral component of the HCV cascade of care and that efforts might be best targeted to individuals with greater socioeconomic disadvantage.
BACKGROUND:Knowledge of hepatitis C virus (HCV) is believed to be important in altering risk behaviour, improving engagement in care, and promoting willingness to initiate HCV treatment. We assessed factors associated with HCV knowledge and treatment willingness amongst people who inject drugs (PWID) in an era of direct acting antivirals. METHODS: Data were derived from three prospective cohort studies of PWID in Vancouver, Canada, between June 2014 and May 2015. HCV knowledge and treatment willingness were assessed using a Likert scale. Multivariable linear regression identified factors associated with higher HCV knowledge and treatment willingness. RESULTS: Amongst 630 participants, mean scores for HCV knowledge and treatment willingness were 25.41 (standard deviation [SD]: 2.52) out of 30, and 6.83 (SD: 1.83) out of 10, respectively. In multivariable analyses, Caucasian ancestry (adjusted linear regression model estimate [β] 0.50; 95% confidence interval [CI] 0.17, 0.82), employment (β 0.76; 95% CI: 0.38, 1.13), diagnosed mental health disorder (β 0.44; 95% CI: 0.11, 0.78) and previous HCV treatment (β 0.94; 95% CI: 0.46, 1.43) were independently associated with higher knowledge. Downtown Eastside (DTES) residence (i.e., epicenter of Vancouver's drug scene) was independently associated with lower knowledge (β -0.48; 95% CI: -0.81, -0.15). Greater HCV knowledge (β 0.12; 95% CI: 0.07, 0.17) was independently associated with higher HCV treatment willingness. DTES residence (β -0.31; 95% CI: -0.56, -0.06) and daily crack cocaine smoking (β -0.52; 95% CI: -0.92, -0.13) were independently associated with lower treatment willingness. CONCLUSION: Socioeconomic factors, such as neighborhood residence and employment, were associated with HCV knowledge. Higher HCV knowledge was associated with more HCV treatment willingness. Our findings suggest that increasing HCV knowledge amongst PWID may be an integral component of the HCV cascade of care and that efforts might be best targeted to individuals with greater socioeconomic disadvantage.
Authors: Kelly E Dunn; Kathryn A Saulsgiver; Mollie E Patrick; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon Journal: Drug Alcohol Depend Date: 2013-08-30 Impact factor: 4.492
Authors: W R Kim; J R Lake; J M Smith; M A Skeans; D P Schladt; E B Edwards; A M Harper; J L Wainright; J J Snyder; A K Israni; B L Kasiske Journal: Am J Transplant Date: 2015-01 Impact factor: 8.086
Authors: A D Marshall; M Micallef; A Erratt; J Telenta; C Treloar; H Everingham; S C Jones; N Bath; D How-Chow; J Byrne; P Harvey; A Dunlop; M Jauncey; P Read; T Collie; G J Dore; J Grebely Journal: Int J Drug Policy Date: 2015-07-16
Authors: Brianna L Norton; Corrine I Voils; Sarah H Timberlake; Emily J Hecker; Neela D Goswami; Kim M Huffman; Anneka Landgraf; Susanna Naggie; Jason E Stout Journal: BMC Infect Dis Date: 2014-02-10 Impact factor: 3.090
Authors: Eshan U Patel; Sunil S Solomon; Allison M Mcfall; Aylur K Srikrishnan; Amrose Pradeep; Paneerselvam Nandagopal; Oliver Laeyendecker; Aaron A R Tobian; David L Thomas; Mark S Sulkowski; M Suresh Kumar; Shruti H Mehta Journal: Int J Drug Policy Date: 2018-04-19
Authors: David Chromy; Philipp Schwabl; Theresa Bucsics; Bernhard Scheiner; Robert Strassl; Florian Mayer; Maximilian C Aichelburg; Katharina Grabmeier-Pfistershammer; Michael Trauner; Markus Peck-Radosavljevic; Thomas Reiberger; Mattias Mandorfer Journal: Wien Klin Wochenschr Date: 2017-07-25 Impact factor: 1.704
Authors: Kiana Yazdani; Katerina Dolguikh; Wendy Zhang; Sara Shayegi-Nik; Jessica Ly; Shaughna Cooper; Jason Trigg; Sophia Bartlett; Rolando Barrios; Julio S G Montaner; Kate Salters Journal: PLoS One Date: 2022-03-23 Impact factor: 3.240
Authors: Jacqueline A Richmond; Jeanne Ellard; Jack Wallace; Rachel Thorpe; Peter Higgs; Margaret Hellard; Alexander Thompson Journal: Hepatol Med Policy Date: 2018-08-04